{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T02:34:43Z","timestamp":1785551683001,"version":"3.56.0"},"reference-count":42,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic & Medicinal Chemistry"],"published-print":{"date-parts":[[2021,1]]},"DOI":"10.1016\/j.bmc.2020.115958","type":"journal-article","created":{"date-parts":[[2020,12,20]],"date-time":"2020-12-20T22:14:19Z","timestamp":1608502459000},"page":"115958","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":61,"special_numbering":"C","title":["[1,2,4]Triazolo[4,3-c]quinazoline and bis([1,2,4]triazolo)[4,3-a:4\u2032,3\u2032-c]quinazoline derived DNA intercalators: Design, synthesis, in silico ADMET profile, molecular docking and anti-proliferative evaluation studies"],"prefix":"10.1016","volume":"30","author":[{"given":"Khaled","family":"El-Adl","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed-Kamal","family":"Ibrahim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed S.I.","family":"Alesawy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6955-2263","authenticated-orcid":false,"given":"Ibrahim H.","family":"Eissa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.bmc.2020.115958_b0005","doi-asserted-by":"crossref","first-page":"1700240","DOI":"10.1002\/ardp.201700240","article-title":"Design, Synthesis, Molecular Docking, and Anticancer Activity of Phthalazine Derivatives as VEGFR-2 Inhibitors","volume":"350","author":"El-Helby","year":"2017","journal-title":"Arch Pharm"},{"key":"10.1016\/j.bmc.2020.115958_b0010","doi-asserted-by":"crossref","first-page":"915","DOI":"10.2174\/1385272003375978","article-title":"Intercalative binding of small molecules to nucleic acids","volume":"4","author":"Graves","year":"2000","journal-title":"Curr Org Chem"},{"key":"10.1016\/j.bmc.2020.115958_b0015","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1006\/meth.1998.0584","article-title":"Stacking interactions and intercalative DNA binding","volume":"14","author":"Gago","year":"1998","journal-title":"Methods"},{"key":"10.1016\/j.bmc.2020.115958_b0020","series-title":"Medicinal Chemistry of Anticancer Drugs","first-page":"199","article-title":"DNA Intercalators and topoisomerase inhibitors","author":"Avendano","year":"2008"},{"key":"10.1016\/j.bmc.2020.115958_b0025","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1124\/pr.56.2.6","article-title":"Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity","volume":"56","author":"Minotti","year":"2004","journal-title":"Pharmacol Rev"},{"key":"10.1016\/j.bmc.2020.115958_b0030","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1023\/A:1008018106064","article-title":"Structure\u2013affinity relationships for the binding of actinomycin D to DNA","volume":"11","author":"Gallego","year":"1997","journal-title":"J Comput Aided Mol Des"},{"issue":"10","key":"10.1016\/j.bmc.2020.115958_b0035","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1093\/bioinformatics\/btx006","article-title":"A DNA intercalation methodology for an efficient prediction of ligand binding pose and energetics","volume":"33","author":"Soni","year":"2017","journal-title":"Bioinformatics"},{"issue":"17","key":"10.1016\/j.bmc.2020.115958_b0040","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.2174\/1381612013397113","article-title":"Intercalators as anticancer drugs","volume":"7","author":"Bra\u00f1a","year":"2001","journal-title":"Curr Pharm Des"},{"key":"10.1016\/j.bmc.2020.115958_b0045","doi-asserted-by":"crossref","first-page":"915","DOI":"10.2174\/1385272003375978","article-title":"Intercalating binding of small molecules to nucleic acids","volume":"4","author":"Graves","year":"2000","journal-title":"Curr Org Chem"},{"issue":"3","key":"10.1016\/j.bmc.2020.115958_b0050","first-page":"811","article-title":"DNA intercalators and using them as anticancer drugs","volume":"2","author":"Goftar","year":"2014","journal-title":"Int J Adv Biol Biom Res"},{"issue":"1\u20132","key":"10.1016\/j.bmc.2020.115958_b0055","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.mrfmmm.2007.03.008","article-title":"Noncovalent Interactions With DNA: An Overview","volume":"623","author":"Strekowski","year":"2007","journal-title":"Mutat Res"},{"key":"10.1016\/j.bmc.2020.115958_b0060","first-page":"212","article-title":"Chemistry and biology of DNA-binding small molecules","volume":"102","author":"Paul","year":"2012","journal-title":"Curr Sci"},{"key":"10.1016\/j.bmc.2020.115958_b0065","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1007\/s12038-012-9212-8","article-title":"Structural studies on ligand\u2014DNA system. A rubst approach in drug design","volume":"37","author":"Kumar","year":"2012","journal-title":"J Biosci"},{"key":"10.1016\/j.bmc.2020.115958_b0070","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1021\/bi00221a013","article-title":"Kinetic and equilibrium analysis of a threading intercalation mode: DNA sequence and ion effects","volume":"30","author":"Tanious","year":"1991","journal-title":"Biochemistry"},{"key":"10.1016\/j.bmc.2020.115958_b0075","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1021\/ar100140e","article-title":"Metal complexes as DNA intercalators","volume":"44","author":"Liu","year":"2011","journal-title":"Acc Chem Res"},{"key":"10.1016\/j.bmc.2020.115958_b0080","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/j.copbio.2007.09.006","article-title":"DNA as a target for anticancer compounds: Methods to determine the mode of binding and the mechanism of action","volume":"18","author":"Palchaudhuri","year":"2007","journal-title":"Curr Opin Biotechnol"},{"key":"10.1016\/j.bmc.2020.115958_b0085","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1246\/bcsj.72.327","article-title":"Threading intercalators as a new DNA structural probe","volume":"72","author":"Takenaka","year":"1999","journal-title":"Bull Chem Soc Jpn"},{"key":"10.1016\/j.bmc.2020.115958_b0095","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1146\/annurev.bi.58.070189.002031","article-title":"DNA topoisomerase poisons as antitumor drugs","volume":"58","author":"Liu","year":"1989","journal-title":"Annu Rev Biochem"},{"key":"10.1016\/j.bmc.2020.115958_b0100","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.bmc.2008.11.072","article-title":"Synthesis and antitumor activity of novel amsacrine analogs: the critical role of the acridine moiety in determining their biological activity","volume":"17","author":"Chilin","year":"2009","journal-title":"Bioorg Med Chem"},{"key":"10.1016\/j.bmc.2020.115958_b0105","doi-asserted-by":"crossref","first-page":"67","DOI":"10.7326\/0003-4819-105-1-67","article-title":"Mitoxantrone: a new anticancer drug with significant clinical activity","volume":"105","author":"Shenkenberg","year":"1986","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.bmc.2020.115958_b0110","doi-asserted-by":"crossref","first-page":"9913","DOI":"10.1021\/bi00452a006","article-title":"Antitumor drug nogalamycin binds DNA in both grooves simultaneously: molecular structure of nogalamycin-DNA complex","volume":"28","author":"Liaw","year":"1989","journal-title":"Biochemistry"},{"key":"10.1016\/j.bmc.2020.115958_b0115","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1016\/j.bmc.2010.12.037","article-title":"Benzoquinazoline derivatives as new agents affecting DNA processing","volume":"19","author":"Marzaro","year":"2011","journal-title":"Bioorg Med Chem"},{"key":"10.1016\/j.bmc.2020.115958_b0120","doi-asserted-by":"crossref","first-page":"5543","DOI":"10.1021\/jm020285l","article-title":"Pyrimidoquinazoline-based antitumor agents. Design of topoisomerase II to DNA cross-linkers with activity against protein kinases","volume":"45","author":"Skibo","year":"2002","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2020.115958_b0125","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1016\/j.bmcl.2003.12.048","article-title":"Novel quinazoline\u2013quinoline alkaloids with cytotoxic and DNA topoisomerase II inhibitory activities","volume":"14","author":"Ma","year":"2004","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.bmc.2020.115958_b0130","doi-asserted-by":"crossref","first-page":"3385","DOI":"10.1016\/j.bmcl.2004.04.094","article-title":"6-Arylamino-7-chloro-quinazoline-5, 8-diones as novel cytotoxic and DNA topoisomerase inhibitory agents","volume":"14","author":"Park","year":"2004","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.bmc.2020.115958_b0135","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.ejmech.2018.04.056","article-title":"Structure-based design of novel quinoxaline-2-carboxylic acids and analogues as Pim-1 inhibitors","volume":"154","author":"Oyallon","year":"2018","journal-title":"Eur J Med Chem"},{"issue":"22","key":"10.1016\/j.bmc.2020.115958_b0140","doi-asserted-by":"crossref","first-page":"8089","DOI":"10.1021\/jm1009605","article-title":"Design, synthesis, and DNA-binding of N-alkyl(anilino)quinazoline derivatives","volume":"53","author":"Garofalo","year":"2010","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2020.115958_b0145","article-title":"5-(4-Methoxybenzylidene)thiazolidine-2,4-dione-derived VEGFR-2 inhibitors: Design, synthesis, molecular docking, and anticancer evaluations","author":"El-Adl","year":"2020","journal-title":"Arch Pharm"},{"key":"10.1016\/j.bmc.2020.115958_b0150","doi-asserted-by":"crossref","first-page":"e2000068","DOI":"10.1002\/ardp.202000068","article-title":"Design, synthesis, molecular docking, and anticancer evaluations of 1-benzylquinazoline-2,4(1H,3H)-dione bearing different moieties as VEGFR-2 inhibitors","author":"El-Adl","year":"2020","journal-title":"Arch Pharm"},{"key":"10.1016\/j.bmc.2020.115958_b0155","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2020.104059","article-title":"Design, synthesis, molecular docking and anticancer evaluations of 5-benzylidenethiazolidine-2,4-dione derivatives targeting VEGFR-2 enzyme","author":"El-Adl","year":"2020","journal-title":"Bioorg Chem"},{"issue":"12","key":"10.1016\/j.bmc.2020.115958_b0160","doi-asserted-by":"crossref","first-page":"1900178","DOI":"10.1002\/ardp.201900178","article-title":"Benzoxazole\/benzothiazole-derived VEGFR-2 inhibitors: Design, synthesis, molecular docking, and anticancer evaluations","volume":"352","author":"El-Helby","year":"2019","journal-title":"Arch Pharm"},{"issue":"10","key":"10.1016\/j.bmc.2020.115958_b0165","doi-asserted-by":"crossref","first-page":"1900113","DOI":"10.1002\/ardp.201900113","article-title":"Design, synthesis, molecular docking, and anticancer activity of benzoxazole derivatives as VEGFR-2 inhibitors","volume":"352","author":"El-Helby","year":"2019","journal-title":"Arch Pharm"},{"issue":"8","key":"10.1016\/j.bmc.2020.115958_b0170","first-page":"1184","article-title":"Design, synthesis, in vitro anti-cancer activity, ADMET profile and molecular docking of novel Triazolo [3, 4-a] phthalazine derivatives targeting VEGFR-2 Enzyme","volume":"18","author":"El-Helby","year":"2018","journal-title":"Anti-Cancer Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry-Anti-Cancer Agents)"},{"key":"10.1016\/j.bmc.2020.115958_b0175","doi-asserted-by":"crossref","first-page":"11493","DOI":"10.1021\/bi00204a011","article-title":"Binding of actinomycin D to the T (G) nT motif of double-stranded DNA: determination of the guanine requirement in nonclassical, non-GpC binding sites","volume":"33","author":"Bailey","year":"1994","journal-title":"Biochemistry"},{"issue":"1\u20132","key":"10.1016\/j.bmc.2020.115958_b0180","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/0022-1759(83)90303-4","article-title":"Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays","volume":"65","author":"Mosmann","year":"1983","journal-title":"J Immunol Methods"},{"issue":"17","key":"10.1016\/j.bmc.2020.115958_b0185","first-page":"4827","article-title":"Evaluation of a soluble tetrazolium\/formazan assay for cell growth and drug sensitivity in culture using human and other tumor cell lines","volume":"48","author":"Scudiero","year":"1988","journal-title":"Cancer Res"},{"issue":"8","key":"10.1016\/j.bmc.2020.115958_b0190","doi-asserted-by":"crossref","first-page":"3727","DOI":"10.1128\/AEM.65.8.3727-3729.1999","article-title":"The MTT [3-(4,5-Dimethylthiazol-2-yl)-2,5-Diphenyltetrazolium Bromide] Assay Is a Fast and Reliable Method for Colorimetric Determination of Fungal Cell Densities","volume":"65","author":"Freimoser","year":"1999","journal-title":"Appl Environ Microbiol"},{"key":"10.1016\/j.bmc.2020.115958_b0195","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1021\/np50089a004","article-title":"A colorimetric microassay for the detection of agents that interact with DNA","volume":"55","author":"Burres","year":"1992","journal-title":"J Nat Prod"},{"key":"10.1016\/j.bmc.2020.115958_b0200","doi-asserted-by":"crossref","first-page":"1602","DOI":"10.1021\/ci800063v","article-title":"Molecular docking of intercalators and groove-binders to nucleic acids using Autodock and Surflex","volume":"48","author":"Holt","year":"2008","journal-title":"J Chem Inf Model"},{"issue":"6041","key":"10.1016\/j.bmc.2020.115958_b0205","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1126\/science.1204117","article-title":"Structural basis of type II topoisomerase inhibition by the anticancer drug etoposide","volume":"333","author":"Wu","year":"2011","journal-title":"Science"},{"key":"10.1016\/j.bmc.2020.115958_b0210","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/BF02524552","article-title":"Antitumor activity of the fluorinated derivatives of condensed quinolines and quinazolines","volume":"34","author":"Lipunova","year":"2000","journal-title":"Pharm Chem J"},{"key":"10.1016\/j.bmc.2020.115958_b0215","doi-asserted-by":"crossref","first-page":"5543","DOI":"10.1021\/jm020285l","article-title":"Pyrimidoquinazoline-based antitumor agents. Design of topoisomerase II to DNA cross-linkers with activity against protein kinases","volume":"45","author":"Skibo","year":"2002","journal-title":"J Med Chem"}],"container-title":["Bioorganic & Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0968089620307884?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0968089620307884?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T01:12:11Z","timestamp":1760836331000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0968089620307884"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1]]},"references-count":42,"alternative-id":["S0968089620307884"],"URL":"https:\/\/doi.org\/10.1016\/j.bmc.2020.115958","relation":{},"ISSN":["0968-0896"],"issn-type":[{"value":"0968-0896","type":"print"}],"subject":[],"published":{"date-parts":[[2021,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"[1,2,4]Triazolo[4,3-c]quinazoline and bis([1,2,4]triazolo)[4,3-a:4\u2032,3\u2032-c]quinazoline derived DNA intercalators: Design, synthesis, in silico ADMET profile, molecular docking and anti-proliferative evaluation studies","name":"articletitle","label":"Article Title"},{"value":"Bioorganic & Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bmc.2020.115958","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"115958"}}